MinterEllison guides sale of Nucleus Network to Crescent Capital Partners
MinterEllison has advised the Baker Heart and Diabetes Institute on the sale of 100% of clinical research company Nucleus Network Limited to private equity firm Crescent Capital Partners.
Based in Melbourne, the Nucleus Network is Australia’s leading early phase clinical research facility. It was established in 2003 and employs more than 100 employees, conducting trials for a range of global biotechnology and pharmaceutical clients.
The sale will boost the Victorian and Australian biotechnology and medical research sectors.